Skip to main content
. 2017 Oct 27;8:769. doi: 10.3389/fphar.2017.00769

Figure 9.

Figure 9

Key metabolic enzymes and transporters interacting with CPT-11 and its metabolites in the liver and intestinal epithelium. SXD altered the pharmacokinetics of CPT-11 by inhibiting Mrp-2 and P-gp expressions and altering the activities/expressions of CES2 and UDP-glucuronosyltransferase.